Evidence map›Paper›PMID 39016996›Full record

ReviewMicrobial biotechnology2024

Preserving the efficacy of antibiotics to tackle antibiotic resistance.

Pablo Laborda, Teresa Gil-Gil, José Luis Martínez, Sara Hernando-Amado

Abstract readReview
In one paragraph

Review in Microbial biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Microbes Saving Lives and Reducing Suffering.Microbial biotechnology · 2025
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Pablo LabordaDepartment of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark.ORCID 0000-0001-8281-7900
Teresa Gil-GilDepartment of Biology, Emory University, Atlanta, Georgia, USA.ORCID 0000-0003-0136-3965
José Luis MartínezCentro Nacional de Biotecnología, CSIC, Madrid, Spain.ORCID 0000-0001-8813-7607
Sara Hernando-AmadoCentro Nacional de Biotecnología, CSIC, Madrid, Spain.ORCID 0000-0001-5822-4996

Funding

MCIN/AEI /10.13039/501100011033 PID2020-113521RB-I00
6 · The paper itself

Abstract

Different international agencies recognize that antibiotic resistance is one of the most severe human health problems that humankind is facing. Traditionally, the introduction of new antibiotics solved this problem but various scientific and economic reasons have led to a shortage of novel antibiotics at the pipeline. This situation makes mandatory the implementation of approaches to preserve the efficacy of current antibiotics. The concept is not novel, but the only action taken for such preservation had been the 'prudent' use of antibiotics, trying to reduce the selection pressure by reducing the amount of antibiotics. However, even if antibiotics are used only when needed, this will be insufficient because resistance is the inescapable outcome of antibiotics' use. A deeper understanding of the alterations in the bacterial physiology upon acquisition of resistance and during infection will help to design improved strategies to treat bacterial infections. In this article, we discuss the interconnection between antibiotic resistance (and antibiotic activity) and bacterial metabolism, particularly in vivo, when bacteria are causing infection. We discuss as well how understanding evolutionary trade-offs, as collateral sensitivity, associated with the acquisition of resistance may help to define evolution-based therapeutic strategies to fight antibiotic resistance and to preserve currently used antibiotics.

Indexed as

Anti-Bacterial AgentsBacteriaBacterial InfectionsDrug Resistance, BacterialAnimalsHumansAnti-Bacterial Agents

Identifiers

PMID39016996
PMCPMC11253305

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.